A5102991642- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Cancer therapeutics and mechanisms
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Neutropenia and Cancer Infections
- PI3K/AKT/mTOR signaling in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Musculoskeletal synovial abnormalities and treatments
- Nausea and vomiting management
- Biochemical and Molecular Research
- Colorectal and Anal Carcinomas
- Pharmacological Effects and Toxicity Studies
- HER2/EGFR in Cancer Research
- Urologic and reproductive health conditions
- Palliative Care and End-of-Life Issues
- Metastasis and carcinoma case studies
- Multiple and Secondary Primary Cancers
- Genital Health and Disease
- Cancer, Lipids, and Metabolism
Azienda Ospedaliera S.Giuseppe Moscati
2009-2025
Sun Yat-sen University
2022
Chinese Academy of Medical Sciences & Peking Union Medical College
2022
The First Affiliated Hospital, Sun Yat-sen University
2022
Zhongshan Hospital
2022
Fudan University
2022
University Hospital Heidelberg
2004-2013
University Medical Center Hamburg-Eppendorf
2013
Heidelberg University
2004-2013
Universität Hamburg
2013
To evaluate whether two commonly used newer platinum-based regimens offer any advantage over vinorelbine-cisplatin (reference regimen) in response rate for patients with advanced non-small-cell lung cancer (NSCLC).Chemotherapy-naive were randomized to receive gemcitabine 1,250 mg/m(2) days 1 and 8 plus cisplatin 75 day 2 every 21 (GC arm), or paclitaxel 225 (3-hour infusion) then carboplatin (area under the concentration-time curve of 6 mg/mL x min), both on (PCb vinorelbine 25 mg/m(2)/wk 12...
Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and updated safety data. Patients Methods all, 939 patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) received four cycles pemetrexed-cisplatin induction therapy; then, 539 no Eastern Cooperative Oncology Group performance status 0 or...
PURPOSE: To compare gemcitabine and cisplatin (GC) with mitomycin, ifosfamide, (MIC) chemotherapy in patients stage IIIB (limited to T4 for pleural effusion N3 supraclavicular lymph nodes) or IV non–small-cell lung cancer (NSCLC). The end points were the evaluation of quality life (QoL), response rates, survival, toxicity. PATIENTS AND METHODS: Three hundred seven randomized receive either 1,000 mg/m 2 on days 1, 8, 15 plus 100 day 2, every 28 days, mitomycin 6 , ifosfamide 3,000 mesna 1...
PURPOSE: To investigate the activity and toxicity of gemcitabine as a single agent in patients with advanced non–small-cell lung cancer (NSCLC) after recurrence or failure previous treatment platinum-containing regimen. PATIENTS AND METHODS: From November 1995 to October 1997, 83 stage IIIB IV NSCLC received 1,000 mg/m 2 once week for 3 weeks every 28 days. Responses were assessed two courses. The median age was 63 years; Eastern Cooperative Oncology Group performance status 0 1 62 21...
CRA7510 The full, final text of this abstract will be available in Part II the 2011 Annual Meeting Proceedings, distributed onsite at on June 4, 2011, and as a supplement to 20, issue Journal Clinical Oncology.
The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance significantly reduced the risk of disease progression (hazard ratio = 0.62) and death 0.78) versus placebo in patients with advanced nonsquamous non-small-cell lung cancer. To further understand survival data, descriptive subgroup analyses were undertaken.Nine hundred thirty-nine received induction therapy (four 21-day cycles 500 mg/m cisplatin 75 mg/m), after which 539 nonprogressing an Eastern Cooperative...
7081 Background: The activity and tolerability of either gemcitabine or vinorelbine given with gefitinib ('Iressa', ZD1839), an Epidermal Growth Factor Receptor-Tyrosine Kinase inhibitor was evaluated in Italian multicentre randomised non-comparative phase II study elderly patients chemo-naive stage IIIB/IV NSCLC using a Fleming's single method. Methods: Fiftynine aged >=70 measurable disease were to receive (250 mg/die orally until progression) plus (30 mg/m2 iv) (armA) (1200 (arm B) both...